Rethinking Molecular Profiling after First-line Osimertinib

作者：Komal Gupta, Daniel S.W. Tan, Regina Hoo · 发表于：Clinical Cancer Research · 年份：2026 · DOI：10.1158/1078-0432.ccr-26-0749 · 研究领域：Lung Cancer Treatments and Mutations、Fibroblast Growth Factor Research、Gastrointestinal Tumor Research and Treatment

Summary A recent article presents the largest histogenomic characterization of first-line osimertinib resistance from the ORCHARD study. Dual-modality tissue and plasma sequencing detected resistance alterations in 87% of patients and polyclonal mechanisms in 46% of patients, highlighting the complexity of post-osimertinib biology and raising questions about targeted versus broadly acting regimens in the post-EGFR tyrosine kinase inhibitor setting. See related article by Yu et al., p. XX .